# MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

> **NCT02088112** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 56 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** MEDI4736

## Key facts

- **NCT ID:** NCT02088112
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-24
- **Primary completion:** 2021-03-09
- **Final completion:** 2021-03-09
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02088112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02088112, "MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02088112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*